Colorectal Cancer with Multiple Metastases: Is Palliative Surgery Needed?.
10.3393/jksc.2011.27.5.226
- Author:
Hong Jo CHOI
1
;
Jin Yong SHIN
Author Information
1. Department of Surgery, Dong-A University College of Medicine, Busan, Korea. colonch@donga.ac.kr
- Publication Type:Review
- Keywords:
Metastatic colorectal cancer;
Palliative care;
Chemotherapy
- MeSH:
Antibodies, Monoclonal, Humanized;
Bevacizumab;
Camptothecin;
Cetuximab;
Colorectal Neoplasms;
Cytotoxins;
Fluorouracil;
Hemorrhage;
Humans;
Life Expectancy;
Neoplasm Metastasis;
Organoplatinum Compounds;
Palliative Care;
Quality of Life;
Retrospective Studies;
Unnecessary Procedures
- From:Journal of the Korean Society of Coloproctology
2011;27(5):226-230
- CountryRepublic of Korea
- Language:English
-
Abstract:
In patients with symptomatic incurable metastatic colorectal cancer (mCRC), the goal of resection of the primary lesion is to palliate cancer-related morbidity, including obstruction, bleeding, or perforation. In patients with asymptomatic primary tumors and incurable metastatic disease, however, the necessity of primary tumor resection is less clear. Although several retrospective analyses suggest survival benefit in patients who undergo resection of the primary tumor, applying this older evidence to modern patients is out of date for several reasons. Modern chemotherapy regimens incorporating the novel cytotoxic agents oxaliplatin and irinotecan, as well as the target agents bevacizumab and cetuximab, have improved median survival from less than 1 year with the only available single-agent 5-fluorouracil until the mid-1990s to over 2 years. In addition to significant prolongation of overall survival, combinations of novel chemotherapeutic and target agents have allowed improved local and distant tumor control, decreasing the likelihood of local tumor-related complications requiring surgical resection. Resection of an asymptomatic primary tumor risks surgical complications and may postpone the administration of chemotherapy that may offer both systemic and local control. In conclusion, the morbidity and the mortality of unnecessary surgery or surgery that does not improve quality of life or survival in patients with mCRC of a limited life expectancy should be carefully evaluated. With the availability of effective combinations of chemotherapy and target agents, systemic therapy for the treatment of life-threatening metastases would be a preferable treatment strategy for unresectable asymptomatic patients with mCRC.
